Hadas Nicole R.

Average Profitability
3.18%
Insider Buys Quantity
1
Insider Buys Sum
$119,000.00
Insider Sells Quantity
23
Insider Sells Sum
$955,460.85

Insider Activity of Hadas Nicole R.

According to the SEC Form 4 filings, Hadas Nicole R., being in a position of

  1. SVP, Chief Legal Officer at Akebia Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 25401 share for $35,844,
    over all time since 2014-03-25, has bought 7000 shares for $119,000, and sold 202493 shares for $955,461.

The largest purchase of all time was on 2014-03-25 and amounted to 7000 shares of Akebia Therapeutics, Inc. for $119,000.

The largest sale of all time was on 2017-10-02 and amounted to 15606 shares of Akebia Therapeutics, Inc. for $310,377.

Biography of Hadas Nicole R.

No biography is available at this moment.

2024-05-13SaleAkebia Therapeutics, Inc.
AKBA
SVP, Chief Legal Officer
12,016
0.0056%
$1.26$15,140+3.13%
2024-02-29SaleAkebia Therapeutics, Inc.
AKBA
SVP, Chief Legal Officer
5,974
0.0032%
$1.58$9,439-12.74%
2024-02-27SaleAkebia Therapeutics, Inc.
AKBA
SVP, Chief Legal Officer
7,411
0.0036%
$1.52$11,265-16.46%
2023-05-25SaleAkebia Therapeutics, Inc.
AKBA
SVP, Chief Legal Officer
63,186
0.0346%
$1.22$77,270+3.31%
2023-03-01SaleAkebia Therapeutics, Inc.
AKBA
SVP, Chief Legal Officer
13,034
0.0068%
$0.88$11,437+23.5%
2023-02-27SaleAkebia Therapeutics, Inc.
AKBA
SVP, Chief Legal Officer
6,677
0.0036%
$0.81$5,430+38.48%
2022-03-01SaleAkebia Therapeutics, Inc.
AKBA
SVP, Chief Legal Officer
14,507
0.0082%
$2.17$31,490-80.93%
2022-02-28SaleAkebia Therapeutics, Inc.
AKBA
SVP, Chief Legal Officer
6,555
0.0036%
$2.15$14,125-81.02%
2021-04-01SaleAkebia Therapeutics, Inc.
AKBA
SVP, Chief Legal Officer
1,060
0.0007%
$3.40$3,604-15.92%
2021-03-01SaleAkebia Therapeutics, Inc.
AKBA
SVP, Chief Legal Officer
14,285
0.0094%
$3.40$48,513-14.71%
2020-02-28SaleAkebia Therapeutics, Inc.
AKBA
SVP, Chief Legal Officer
7,050
0.0054%
$8.70$61,335-34.16%
2017-10-02SaleAkebia Therapeutics, Inc.
AKBA
SVP, General Counsel, Sec.
15,606
0.0326%
$19.89$310,377-45.25%
2017-07-03SaleAkebia Therapeutics, Inc.
AKBA
SVP, General Counsel, Sec.
3,108
0.0065%
$14.26$44,313-0.51%
2017-04-03SaleAkebia Therapeutics, Inc.
AKBA
SVP, General Counsel, Sec.
3,112
0.0078%
$9.18$28,560+64.77%
2017-01-01SaleAkebia Therapeutics, Inc.
AKBA
SVP, General Counsel, Sec.
3,620
0.0097%
$10.49$37,976
2016-10-01SaleAkebia Therapeutics, Inc.
AKBA
SVP, General Counsel, Sec.
3,112
0.0082%
$8.95$27,867
2016-07-05SaleAkebia Therapeutics, Inc.
AKBA
SVP, General Counsel, Sec.
3,114
0.0082%
$7.47$23,251+21.67%
2016-04-04SaleAkebia Therapeutics, Inc.
AKBA
SVP, General Counsel, Sec.
3,112
0.0081%
$9.41$29,284-7.02%
2016-01-04SaleAkebia Therapeutics, Inc.
AKBA
SVP, General Counsel, Sec.
3,622
0.0096%
$12.28$44,478-32.72%
2015-10-02SaleAkebia Therapeutics, Inc.
AKBA
SVP, General Counsel, Sec.
2,968
0.0099%
$8.67$25,720-11.81%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.